An inflammation marker is emerging as a tool capable of detecting cardiovascular risks that may remain invisible through routine medical testing, including one associated with stroke. Despite established risk factors such as elevated cholesterol and high blood pressure, these known indicators account for only about half of first heart attack cases. Research suggests that chronic, low-grade inflammation may be responsible for the remaining risk, a condition measurable by assessing high-sensitivity C-reactive protein, or hsCRP.
It is important to note that standard C-reactive protein (CRP) tests are designed to detect or monitor overt inflammatory processes, such as severe infections or autoimmune disorders. In contrast, hsCRP measures a different aspect of inflammation. The utility of hsCRP lies in its ability to quantify subtle, persistent inflammation that contributes to cardiovascular disease progression.
Because many risk factors are not fully accounted for by traditional screenings, measuring this inflammatory marker offers a more comprehensive risk profile. Elevated levels of hsCRP indicate systemic inflammation, which can contribute to plaque buildup in the arteries. Therefore, while traditional tests remain crucial, the inclusion of hsCRP testing provides clinicians with an additional metric.
This allows for a more nuanced assessment of overall cardiovascular risk, potentially identifying individuals who are not currently exhibiting other severe symptoms but possess underlying inflammatory conditions that elevate their susceptibility to major cardiac events.
Topics: #not #high #reactive
